tirzepatide peak sales GLP-1 anti-obesity drugs lead to substantial weight loss in the “real world” Novo Nordisk: Tipping the Scale
Description
This listing identifies Semaglutide in a 10-vial presentation, with a stated strength of 5 mg per vial
)
However, Novos market cap is far lower, under $200 billion, having lost about $400 billion in value since its peak in mid-2024
The constipation makes sense given tirzepatides mechanism
The drug is a once-a-week injection that combines two hormones, GLP-1 and GIP, which work in combination to stimulate insulin secretion and reduce appetite
The relationship between GLP-1 agonists and energy is complex
The reconstitution guide covers the complete process
